Publications by authors named "Zhongyu Zhu"

Are you Zhongyu Zhu?   Register this Author


Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
Cancer Cell 2017 Sep;32(3):295-309.e12
Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Colket Translational Research Building, 3501 Civic Center Boulevard, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:


Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
J Virol 2014 Mar 11;88(5):2426-41. Epub 2013 Dec 11.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.
J Virol 2014 Jan 6;88(2):1125-39. Epub 2013 Nov 6.
Protein Interactions Group, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.



Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.
Antiviral Res 2010 Oct 13;88(1):107-15. Epub 2010 Aug 13.
Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute (NCI)-Frederick, National Institutes of Health (NIH), Frederick, MD 21702-1201, USA.

Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.
PLoS One 2010 Oct 13;5(10):e13047. Epub 2010 Oct 13.
Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, Maryland, United States of America.



A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
Mol Cancer Ther 2009 May 5;8(5):1113-8. Epub 2009 May 5.
Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, NIH, Frederick, Maryland 21702-1201, USA.

Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain.
J Mol Biol 2008 Oct 26;382(3):779-89. Epub 2008 Jul 26.
Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702-1201, USA.

Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.
J Infect Dis 2008 Mar;197(6):846-53
Protein Interactions Group, Center for Cancer Research Nanobiology Program, Center for Cancer Research, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702-1201, USA.

Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra.
J Proteome Res 2007 Nov 9;6(11):4150-62. Epub 2007 Oct 9.
Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC-Frederick, Inc., NCI-Frederick, P.O. Box B, Frederick, Maryland 21702, USA.

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.
Proc Natl Acad Sci U S A 2007 Jul 9;104(29):12123-8. Epub 2007 Jul 9.
Protein Interactions Group, Center for Cancer Research Nanobiology Program, SAIC-Frederick, Inc., National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702, USA.


Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar.
MAbs 2014 30;6(5):1190-200. Epub 2014 Oct 30.
a Protein Interactions Group; Laboratory of Experimental Immunology; Cancer and Inflammation Program; Center for Cancer Research; National Cancer Institute; National Institutes of Health ; Frederick , MD , USA.

Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.
MAbs 2016 May-Jun;8(4):799-810. Epub 2016 Feb 24.
a Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute , Frederick , MD , USA.

Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.
MAbs 2016 May-Jun;8(4):761-74. Epub 2016 Mar 10.
a Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Frederick , Maryland , USA.



OF